| Description | Zamerovimab (CTB011; SYN023), a composite of human monoclonal antibodies CTB011 and CTB012, targets distinct, non-overlapping epitopes on the rabies virus (RABV) glycoprotein, with CTB011 specifically binding to antigenic site III. This compound is applicable in rabies research [1]. |
| In vitro | Zamerovimab（CTB011; SYN023）（0.001-100 μg/mL，4小时）在BSR细胞内的CVS感染中，剂量依赖性地诱导了细胞毒性，有助于病毒的清除；同时证明了这种细胞毒性与G蛋白表达的细胞特异性相关，并由CTB011特异性靶向[1]。 |
| In vivo | Zamerovimab (CTB011; SYN023) (0.03-1.0 mg/kg，IM一次性给药，35天) 能够以剂量依赖性的方式提高RABV BD06感染的叙利亚仓鼠的生存率；具体而言，当剂量为0.03、0.1、0.3、1.0 mg/kg时，仓鼠的生存率分别达到了58%，83%，100% 和 100%[1]。 |
| Synonyms | SYN023, CTB011 |
| molecular weight | N/A |
| CAS | 2419087-87-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |